Table 3.
Summary data from published cases of nivolumab and pembrolizumab in patients with ESKD on dialysisa
| Variable | Total reported cases | Nivolumab | Pembrolizumab |
|---|---|---|---|
| Patients, n (%) | 76 (100) | 45 (59.2) | 31 (40.8) |
| Age at ICI initiation (years), mean (SD) | 64.2 (12.1) | 65.8 (9.2) | 59.4 (11.1) |
| Age at ICI initiation (years), median (IQR) | 66 (58–73) | 67 (63–73) | 60.5 (53.3–67.5) |
| Male, n (%) | 42 (76.4) | 29 (76.3) | 13 (76.5) |
| Female, n (%) | 13 (29.6) | 9 (23.7) | 4 (23.5 |
| Cancer site, n (%) | |||
| RCC | 30 (39.5) | 29 (64.4) | 1 (3.2) |
| Melanoma | 10 (13.2) | 5 (11.1) | 5 (16.1) |
| Urothelial/GU NOS | 15 (19.7) | 5 (11.1) | 10 (32.3) |
| Lung | 5 (6.5) | 2 (4.4) | 3 (9.7) |
| Skin SCC | 4 (5.2) | 0 (0.0) | 4 (12.9) |
| Head and neck | 3 (3.9) | 0 (0.0) | 3 (9.7) |
| Merkle cell | 1 (1.3) | 1 (2.2) | 0 (0.0) |
| Other | 8 (10.5) | 3 (6.7) | 5 (16.1) |
| Dialysis modality, n (%) | |||
| Hemodialysis | 73 (96.1) | 43 (95.6) | 30 (96.8) |
| Peritoneal dialysis | 3 (3.9) | 2 (4.4) | 1 (3.2) |
| Treatment duration (months), median (IQR) | 6.1 (4.4–9.7) | 8.0 (4.6–14.0) | 6.5 (2.9–7.7) |
| irAE (non-renal), n (%) | |||
| irAEs | 47 | – | – |
| Grade 1/2 irAEs | 38 | – | – |
| Grade 3/4 irAEs | 14 | – | – |
| Patients experiencing any irAE | 40 (52.6) | 21 (46.7) | 19 (61.3) |
| Patients experiencing Grade 1/2 | 26 (34.2) | 14 (31.1) | 12 (38.7) |
| Patients experiencing Grade 3/4 | 14 (18.4) | 7 (15.6) | 7 (22.5) |
| irAEs by type, n | |||
| Cutaneous | 5 | – | – |
| Encephalitis | 1 | – | – |
| Endocrine | 4 | – | – |
| GI/diarrhea | 0 | – | – |
| Hematologic | 9 | – | – |
| Hepatitis | 2 | – | – |
| Myocarditis | 1 | – | – |
| Pneumonitis | 3 | – | – |
| Cancer outcomes, n (%) | |||
| Complete remission | 3 (3.9) | 2 (4.4) | 1 (3.2) |
| Partial remission | 20 (26.3) | 13 (28.9) | 7 (22.5) |
| Stable disease | 22 (28.9) | 15 (33.3) | 7 (22.5) |
| Progressive disease | 26 (34.2) | 12 (26.7) | 14 (45.2) |
| Not available | 5 (6.6) | 3 (6.7) | 2 (6.4) |
| Death | 21 (27.6) | 12 (26.7) | 9 (29.0) |
a
Values and proportions reported for each characteristic among those patient in whom individual (patient-level) data were available.
SCC, squamous cell cancer.